Search | Clinical Trials Finder

Conditions: HIV, Cardiovascular Diseases, Inflammation
Interventions: Aspirin, Clopidogrel; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: New York, New York

Conditions: Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions: Prasugrel, Clopidogrel; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Acute Coronary Syndrome
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more

Conditions: Coronary Artery Disease
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: Rapid City Regional Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rapid City, South Dakota

Conditions: Myocardial Infarction
Interventions: Clopidogrel; Drug
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 21 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Atrial Fibrillation, Cardiovascular Disease
Interventions: Irbesartan, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 9,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Stable Coronary Artery Disease
Interventions: Ticagrelor, Clopidogrel, Aspirin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Not listed
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more

Conditions: Blood Platelets, Clopidogrel
Interventions: clopidogrel + aspirin, placebo, Aspirin; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 21 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Coronary Artery Disease
Interventions: Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin; Drug
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 25,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 178
States / cities: Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more

Conditions: Type-2 Diabetes Mellitus, Coronary Artery Disease
Interventions: Ticagrelor + Aspirin, Clopidogrel + Aspirin; Drug
Lead sponsor: Juan J Badimon; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease
Interventions: Clopidogrel; Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Coronary Artery Disease, Chest Pain
Interventions: Clopidogrel; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Percutaneous Coronary Intervention
Interventions: clopidogrel, PRT060128; Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 19
States / cities: La Jolla, California • Torrance, California • Washington D.C., District of Columbia + 16 more

Conditions: Chronic Kidney Diseases, Acute Coronary Syndrome
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: North Texas Veterans Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina • Dallas, Texas

Conditions: Coronary Artery Disease
Interventions: Prasugrel, Clopidogrel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: HIV-1 Infection
Interventions: Clopidogrel, Aspirin, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Type2 Diabetes, Antiplatelet Drugs, Myocardial Infarction, Heart Failure
Interventions: Antiplatelet Drug; Drug
Lead sponsor: Tabula Rasa HealthCare; Industry
Eligibility: 18 Years and older
Enrollment: 173,464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Coronary Artery Disease
Interventions: PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Loveland, Colorado • Petoskey, Michigan

Conditions: Heart Defects, Congenital
Interventions: Clopidogrel (SR25990), placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Up to 92 Days
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Peripheral Arterial Disease
Interventions: edoxaban, Clopidogrel, Aspirin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 23 more

Conditions: Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions: cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 11,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Anderson, South Carolina

Search by objective public record fields.

Antiplatelet Therapy in HIV

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

YouScript IMPACT Registry

PACT (Platelet Activity After Clopidogrel Termination)

Quality Improvement and Practice Based Research in Neurology Using the EMR

The Dual Antiplatelet Therapy Study (DAPT Study)

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

Pilot Study on the Effect of High Clopidogrel Maintenance Dosing

The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

Targeting Platelets in Chronic HIV Infection

Type 2 Diabetes With Antiplatelet Drugs

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation

Edoxaban in Peripheral Arterial Disease

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)